Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/32306

Type
Article
Copyright
Open access
Collections
Share

Statistics
Metadata
Show full item record

THE HIV CURE RESEARCH AGENDA: THE ROLE OF MATHEMATICAL MODELLING AND COST-EFFECTIVENESS ANALYSIS
Freedberg, Kenneth A. et al. | Date Issued: 2015
Author
Freedberg, Kenneth A.
Possas, Cristina
Deeks, Steven
Ross, Anna Laura
Rosettie, Katherine L.
Mascio, Michele Di
Collins, Chris
Walensky, Rochelle P.
Yazdanpanah, Yazdan
Affilliation
Divisions of General Internal Medicine and Infectious Disease, Massachusetts General Hospital, Boston, USA / Harvard TH Chan School of Public Health. Department of Health Policy and Management. Boston, USA.
Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, RJ, Brazil.
San Francisco General Hospital. University of California San Francisco. Department of Medicine.San Francisco, CA, USA / National Institutes of Health. Department of Health and Human Services. Bethesda, MD, USA.
International AIDS Society, Geneva, Switzerland / ANRS. International and Scientific Relations Office. Paris, France.
National Institute of Allergy and Infectious Diseases. Division of Clinical Research. National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
National Institute of Allergy and Infectious Diseases. Division of Clinical Research. National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Community Mobilization Division. Geneva, Switzerland.
Joint United Nations Programme on HIV/AIDS (UNAIDS). Community Mobilization Division. Geneva, Switzerland / Brigham and Women's Hospital.Division of Infectious Disease. Boston, MA, USA.
INSERM / Université Paris Diderot, IAM. Sorbonne Paris Cité / Hôpital Bichat. Services de Maladies Infectieuses et Tropicales. Paris, France.
Abstract
The research agenda towards an HIV cure is building rapidly. In this article, we discuss the reasons for and methodological approach to using mathematical modelling and cost-effectiveness analysis in this agenda. We provide a brief description of the proof of concept for cure and the current directions of cure research. We then review the types of clinical economic evaluations, including cost analysis, cost-benefit analysis and cost-effectiveness analysis. We describe the use of mathematical modelling and cost-effectiveness analysis early in the HIV epidemic as well as in the era of combination antiretroviral therapy. We then highlight the novel methodology of Value of Information (VOI) analysis and its potential role in the planning of clinical trials. We close with recommendations for modelling and cost-effectiveness analysis in the HIV cure agenda.
Keywords
HIV/AIDS
Cost-effectiveness
Cure
Mathematical modeling
 
Citation
FREEDBERG, Kenneth A. et al. The HIV cure research agenda: the role of mathematical modelling and cost-effectiveness analysis. Journal Of Virus Eradication, London, v. 4, n. 1, p. 245-249, 2015.
ISSN
2055-6640
Notes
For the International AIDS Society Working Group on Cost-Effectiveness: Towards an HIV Cure Initiative.